Antares Pharma, Inc. (ATRS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Antares Pharma, Inc. (ATRS) trades at $5.59 with AI Score 56/100 (Grade B). Antares Pharma, Inc. is a specialty pharmaceutical company focused on developing innovative drug delivery systems. Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for ATRS: ATRS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ATRS against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ATRS: 3/6 perspectives are bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Antares Pharma, Inc. (ATRS) Healthcare & Pipeline Overview
Antares Pharma, Inc. specializes in innovative drug delivery systems, providing tailored pharmaceutical solutions for unmet patient needs across endocrinology, rheumatology, and other therapeutic areas, positioning itself as a key player in the specialty pharmaceutical market.
What Is the Investment Thesis for ATRS?
Antares Pharma, Inc. demonstrates a strong investment thesis characterized by a P/E ratio of 20.5 and a profit margin of 25.2%, indicating effective cost management and profitability. The company's focus on innovative drug delivery systems positions it well within the growing specialty pharmaceutical market, which is expected to expand significantly in the coming years. Key growth catalysts include the continued success of its flagship products, such as XYOSTED and OTREXUP, as well as the potential for new product launches in the diabetes and oncology sectors. The ongoing partnerships with major pharmaceutical companies enhance its research and development capabilities, providing a competitive edge. However, risks such as regulatory hurdles and market competition must be carefully monitored as they could impact future growth trajectories.
Based on FMP financials and quantitative analysis
ATRS Key Highlights
- P/E ratio of 20.5 indicates strong valuation relative to earnings.
- Profit margin of 25.2% showcases effective cost management and profitability.
- Gross margin of 62.9% exceeds industry averages, highlighting operational efficiency.
- Beta of 1.15 suggests moderate volatility compared to the overall market.
- No dividend yield reflects a focus on reinvestment for growth.
Who Are ATRS's Competitors?
ATRS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $366.92 | +0.13% | $198.03B | 82 |
| ABBV AbbVie Inc. | $254.71 | -0.02% | $450.02B | 78 |
| TEVA Teva Pharmaceutical Industries Limited | $34.65 | -1.81% | $40.35B | 44 |
| NYXH Nyxoah S.A. | $1.62 | -8.47% | $64.16M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $28.08 | +0.73% | $1.64B | 67 |
| ZTEK Zentek Ltd. | $0.51 | +10.73% | $55.26M | 63 |
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.77M | 61 |
| TDVXF Tobii Dynavox AB (publ) | $6.79 | +13.57% | $719.76M | 56 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ATRS's Key Strengths?
- Innovative drug delivery systems that address specific patient needs.
- Strong profit margins indicating operational efficiency.
- Established partnerships with major pharmaceutical companies.
What Are ATRS's Weaknesses?
- Limited product diversification outside of niche therapeutic areas.
- Dependency on a few key products for revenue generation.
- No dividend yield may deter income-focused investors.
What Could Drive ATRS Stock Higher?
- Regulatory approvals for new products, including TLANDO, expected in the next 12 months.
- Strategic partnerships with major pharmaceutical companies enhancing product development.
- Continued market penetration of existing products like XYOSTED and OTREXUP.
What Are the Key Risks for ATRS?
- Regulatory hurdles that could delay product launches.
- Competition from larger pharmaceutical companies affecting market share.
- Changes in healthcare policies impacting reimbursement for specialty drugs.
What Are the Growth Opportunities for ATRS?
- Expansion into Diabetes Care: Antares Pharma is developing disposable pen injectors for diabetes management, targeting a growing market projected to reach $100 billion by 2028. With the increasing prevalence of diabetes globally, the company's innovative delivery systems can capture significant market share, particularly among patients seeking user-friendly administration options.
- New Product Launches in Oncology: The company is exploring drug/device products for urologic oncology, a sector expected to grow at a CAGR of 7% through 2027. By leveraging its expertise in drug delivery systems, Antares can introduce products that enhance treatment efficacy and patient adherence, positioning itself as a leader in this niche market.
- Strategic Partnerships Expansion: Antares Pharma's existing alliances with Pfizer and Teva provide a foundation for future collaborations. Expanding these partnerships could lead to co-development opportunities, enhancing product offerings and increasing market penetration in various therapeutic areas, particularly in immunology and endocrinology.
- Geographic Market Expansion: The company aims to expand its footprint in international markets, particularly in Europe and Asia, where the demand for innovative drug delivery systems is rising. This expansion could significantly increase revenue streams, especially as healthcare systems in these regions adopt advanced therapeutic solutions.
- Regulatory Approvals for New Products: Antares Pharma is actively pursuing regulatory approvals for several new products, including TLANDO for testosterone deficiency. Successful approvals can lead to increased market access and sales, driving revenue growth in the coming years.
What Opportunities Does ATRS Have?
- Expansion into emerging markets with growing healthcare demands.
- Development of new products in high-growth therapeutic areas.
- Strategic collaborations to enhance product offerings and market access.
What Threats Does ATRS Face?
- Intense competition from larger pharmaceutical companies.
- Regulatory challenges that may delay product approvals.
- Market volatility impacting funding for research and development.
What Are ATRS's Competitive Advantages?
- Strong portfolio of patented drug delivery technologies.
- Established partnerships with leading pharmaceutical companies enhance credibility.
- Focus on niche therapeutic areas reduces direct competition.
- Proven track record of successful product launches and regulatory approvals.
- Expertise in developing user-friendly delivery systems increases patient adherence.
What Does ATRS Do?
Founded in 1979, Antares Pharma, Inc. is a specialty pharmaceutical company headquartered in Ewing, New Jersey. The company focuses on developing and commercializing pharmaceutical products and technologies that address specific patient needs in targeted therapeutic areas. Over the years, Antares has evolved from its initial offerings to become a leader in innovative drug delivery systems, particularly in the fields of endocrinology and rheumatology. Its product portfolio includes XYOSTED, a subcutaneous testosterone replacement therapy for adult males; OTREXUP, a methotrexate injection for severe rheumatoid arthritis; and NOCDURNA, a treatment for nocturia. Antares also produces generic Epinephrine Injection products for severe allergic reactions, Sumatriptan Injection for migraines, and Makena, a subcutaneous auto-injector aimed at reducing preterm birth risks. The company has established strategic alliances with major pharmaceutical players like Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, and AMAG, enhancing its market reach and product development capabilities. As of May 23, 2022, Antares operates as a subsidiary of Halozyme Therapeutics, Inc., further solidifying its position in the pharmaceutical landscape. With a workforce of 201 employees, Antares Pharma continues to focus on addressing unmet medical needs through its innovative product offerings and strategic partnerships.
What Products and Services Does ATRS Offer?
- Develops and commercializes innovative drug delivery systems.
- Offers a range of injection products for various therapeutic areas.
- Focuses on unmet patient needs in endocrinology and rheumatology.
- Partners with major pharmaceutical companies for product development.
- Manufactures generic and proprietary injectable medications.
- Provides solutions for chronic conditions such as diabetes and osteoporosis.
How Does ATRS Make Money?
- Generates revenue through the sale of proprietary and generic injectable medications.
- Engages in strategic partnerships to co-develop and market new products.
- Utilizes innovative drug delivery technologies to enhance patient adherence and outcomes.
- Focuses on niche therapeutic areas with high unmet medical needs.
- Invests in research and development to expand product offerings and market reach.
What Industry Does ATRS Operate In?
The healthcare industry, particularly the medical instruments and supplies sector, is experiencing robust growth driven by increasing demand for innovative therapies and drug delivery systems. The global specialty pharmaceuticals market is projected to expand at a CAGR of approximately 8.5% from 2023 to 2030, reaching an estimated value of $300 billion. Antares Pharma, Inc. is well-positioned within this landscape, leveraging its specialized product offerings to address unmet patient needs. The competitive landscape includes major players such as Amgen and AbbVie, but Antares differentiates itself through its focus on unique drug delivery technologies and strategic partnerships.
Who Are ATRS's Key Customers?
- Healthcare providers and hospitals requiring specialized injectable medications.
- Pharmaceutical companies seeking innovative drug delivery solutions.
- Patients with chronic conditions needing effective treatment options.
- Pharmacies and distributors for the supply of pharmaceutical products.
- Regulatory bodies for compliance and approval of new therapies.
Company Profile
Antares Pharma, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Ewing, US. The company is led by CEO Robert Apple. ATRS has traded publicly since 1996.
ATRS Valuation & Market Position
Relative to its peer group, ATRS's quantitative score of 56/100 is below the peer average of 68/100.
ROE 31%Key Financial Metrics
Return on equity for Antares Pharma, Inc. stands at 31.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 18.0%, showing how much profit it generates from its asset base. ATRS trades at a trailing price-to-earnings ratio of 20.55, below the Healthcare sector average of ~23x. A current ratio of 2.74 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.9%, the inverse of the P/E and a quick read on earnings relative to price.
ATRS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Antares Pharma's growth potential, reflecting a positive outlook from leadership.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative drug delivery systems gaining traction.
- Analysts note the increasing demand for self-administered therapies, positioning Antares favorably in a growing market.
- Recent partnerships have expanded their product pipeline, enhancing investor optimism about future revenue streams.
Bear Case
- Concerns over regulatory hurdles persist, with recent discussions indicating potential delays in product approvals that could impact timelines.
- Some community members express skepticism about the company’s ability to compete against larger pharmaceutical firms with more resources.
- Market perception remains cautious due to previous volatility in stock performance, causing hesitation among new investors.
- Recent earnings reports have not met market expectations, leading to mixed sentiments about the company's short-term profitability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
ATRS Latest News
-
Stocks That Hit 52-Week Lows On Monday
· Mar 23, 2020
-
Stocks That Hit 52-Week Lows On Thursday
· Mar 19, 2020
-
Stocks That Hit 52-Week Lows On Wednesday
· Mar 18, 2020
ATRS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ATRS.
Price Targets
Wall Street price target analysis for ATRS.
ATRS MoonshotScore
What does this score mean?
The MoonshotScore rates ATRS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Robert Apple
CEO
Robert Apple has extensive experience in the pharmaceutical industry, having held various leadership roles in both public and private companies. He has a strong background in business development, product commercialization, and strategic planning. His educational credentials include a degree in business administration, which has equipped him with the skills necessary to lead Antares Pharma effectively.
Track Record: Under Robert Apple's leadership, Antares Pharma has successfully launched several key products, expanded its strategic partnerships, and improved operational efficiencies, contributing to the company's growth and market presence.
ATRS Healthcare Stock FAQ
What does Antares Pharma, Inc. do?
Antares Pharma, Inc. is a specialty pharmaceutical company that develops and commercializes innovative drug delivery systems. The company focuses on addressing unmet patient needs in targeted therapeutic areas, including endocrinology and rheumatology, with a portfolio that includes products for testosterone replacement, rheumatoid arthritis, and nocturia.
What do analysts say about ATRS stock?
Analysts generally view Antares Pharma, Inc. positively, highlighting its innovative product offerings and strong profit margins. Key valuation metrics include a P/E ratio of 20.5, which is considered reasonable for a company in the specialty pharmaceuticals sector, alongside a gross margin of 62.9% that exceeds industry averages.
What are the main risks for ATRS?
Antares Pharma, Inc. faces several risks, including potential regulatory hurdles that could impact product approvals and market entry. Additionally, the company operates in a competitive landscape with larger pharmaceutical firms, which could threaten its market share. Ongoing changes in healthcare policies may also affect reimbursement rates for its specialty drugs.
What are the key factors to evaluate for ATRS?
Antares Pharma, Inc. (ATRS) holds an AI score of 56/100 (moderate). P/E: 20.5x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does ATRS data refresh on this page?
ATRS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ATRS's recent stock price performance?
Antares Pharma, Inc. (ATRS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative drug delivery systems that address specific patient needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ATRS overvalued or undervalued right now?
Antares Pharma, Inc. (ATRS) trades at 20.5x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ATRS?
Before investing in Antares Pharma, Inc. (ATRS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information and may be subject to change.